HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SB 220025
inhibits p38 mitogen-activated protein kinase; structure in first source
Also Known As:
5-(2-amino-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole; SB-220025; SB220025
Networked:
2
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
SB 220025: 2
Pyrimidines: 510
SB 220025: 2
Experts
1.
Kobayashi, Motohiro
: 1 article (11/2007)
2.
Natsume, Tsugitaka
: 1 article (11/2007)
3.
Watanabe, Junichi
: 1 article (11/2007)
Related Diseases
1.
Experimental Arthritis
02/01/1998 - "
To further study the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease, SB 220025 was tested in murine collagen-induced arthritis.
"
2.
Neoplasms (Cancer)
11/01/2007 - "
Gross findings showed that SB220025 visibly attenuated the TZT-1027-induced widespread hemorrhage in tumors.
"
11/01/2007 - "
Pretreatment with docetaxel and SB220025, a p38 mitogen-activated protein kinase (MAPK) inhibitor, significantly suppressed the TZT-1027-induced reduction of tumor perfusion and increase in vascular permeability.
"
3.
Hemorrhage
11/01/2007 - "
Gross findings showed that SB220025 visibly attenuated the TZT-1027-induced widespread hemorrhage in tumors.
"
4.
Arthritis (Polyarthritis)
02/01/1998 - "
In this model, SB 220025 was able to prevent the progression of established arthritis.
"
Related Drugs and Biologics
1.
Phosphotransferases (Kinase)
2.
p38 Mitogen-Activated Protein Kinases
3.
Docetaxel (Taxotere)